Correction - everyone with HSV-1 outbreaks could in my opinion benefit from prophylactic antivirals.

It's worth noting that HSV-1 seroprevalence is extremely heterogeneous. Many nations have rates over 90%, which some Northern European nations have rates of 40% - suggesting broad immunity or reduced transmission. Although this could also be a function of different amounts of research and testing.